Hengrui Pharmaceutical (600276.SH): SHR-1819 injection received drug clinical trial approval notice

Zhitongcaijing · 11/26 08:57

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) announced that recently, Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of the company, received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for SHR-1819 injections and will conduct clinical trials in the near future.

According to the “Drug Administration Law of the People's Republic of China” and related regulations, after review, the SHR-1819 injection clinical trial application accepted on September 4, 2024 met the relevant requirements for drug registration, and it was agreed that this product would carry out phase Ib/II clinical trials. The application is indicated for atopic dermatitis in children and adolescents aged 6-17 years.